Erlotinib Plus Docetaxel in Treating Patients With Stage IV or Recurrent Breast Cancer

NCT00054275 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

39

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: docetaxel
DRUG: erlotinib hydrochloride

Sponsor

Paula Silverman, MD

Collaborators

[object Object]